Showing results (41-50 of 118) with videos related to
Sort By:
Pageof 12
Cancers|November 11, 2022
The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung CancerKaram Khaddour, Manuel Felipe Fernandez, Marsel Khabibov, et al.Cancer|September 2, 2016
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113Rachel E Sanborn, Jyoti D Patel, Gregory A Masters, et al.Clinical Lung Cancer|March 14, 2026
Unmet Need and Treatment Expectations of Previously Treated Patients With Epidermal Growth Factor Receptor-Mutated Advanced Nonsmall Cell Lung Cancer: A Qualitative Interview StudyJyoti D Patel, Jie Meng, Aura Cecilia Jimenez-Moreno, et al.Clinical Lung Cancer|July 28, 2009
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJyoti D Patel, Philip Bonomi, Mark A Socinski, et al.American Journal of Clinical Oncology|January 29, 2015
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak TrialsCorey J Langer, Mark A Socinski, Jyoti D Patel, et al.Journal of Neuro-Oncology|January 20, 2022
Leptomeningeal metastases: the future is nowRimas V Lukas, Jigisha P Thakkar, Massimo Cristofanilli, et al.Oncotarget|February 14, 2018
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancerShalin Shah, Kevin Wood, Brian Labadie, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2015
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsMelissa L Johnson, Helena A Yu, Eric M Hart, et al.Cancers|November 9, 2024
The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health SystemChetan V Vakkalagadda, Danielle B Dressler, Zequn Sun, et al.The Annals of Thoracic Surgery|October 29, 2015
Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung CancerRavi Rajaram, Jennifer L Paruch, Sanjay Mohanty, et al.Pageof 12